196 related articles for article (PubMed ID: 36857853)
1. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
3. Prescribing of disease modifying agents in older adults with multiple sclerosis.
Talwar A; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
[TBL] [Abstract][Full Text] [Related]
4. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
[TBL] [Abstract][Full Text] [Related]
5. Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years.
Ghadiri F; Sahraian MA; Baghbanian SM; Ashtari F; Razazian N; Majdinasab N; Poursadeghfard M; Hatamian H; Harirchian MH; Beladimoghadam N; Azimi A; Sharifipour E; Hosseini S; Bayati A; Kamali H; Hosseni Nejad Mir N; Faraji F; Mozhdehipanah H; Modara F; Navardi S; Heidari H; Ayoubi S; Naser Moghadasi A; Eskandarieh S
Mult Scler Relat Disord; 2022 May; 61():103777. PubMed ID: 35390594
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
7. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
9. How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey.
Morrison EH; Michtich K; Hersh CM
Mult Scler Relat Disord; 2021 Jun; 51():102913. PubMed ID: 33839482
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
11. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Simpson-Yap S; Pirmani A; De Brouwer E; Peeters LM; Geys L; Parciak T; Helme A; Hillert J; Moreau Y; Edan G; Spelman T; Sharmin S; McBurney R; Schmidt H; Bergmann A; Braune S; Stahmann A; Middleton R; Salter A; Bebo B; van der Walt A; Butzkueven H; Ozakbas S; Karabudak R; Boz C; Alroughani R; Rojas JI; van der Mei I; Sciascia do Olival G; Magyari M; Alonso R; Nicholas R; Chertcoff A; Zabalza A; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Kalincik T
Mult Scler Relat Disord; 2022 Oct; 66():104072. PubMed ID: 35917745
[TBL] [Abstract][Full Text] [Related]
12. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
13. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
14. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
18. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
[TBL] [Abstract][Full Text] [Related]
19. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
20. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]